Yaya I Coulibaly, Abdoul F Diabate, Moussa Sangare, Sekou O Thera, Housseini Dolo, Salif S Doumbia, Siaka Y Coulibaly, Ayouba Diarra, Lamine Diarra, Diadje Tanapo, Michel E Coulibaly, Lamine Soumaoro, Abdallah A Diallo, Amatigue Zeguime, Yacouba Sanogo, Adama Berthe, Fatoumata Dite Nene Konipo, Charles Mackenzie, Mariana Stephens, Joseph P Shott, Jayla Norman, Ute Klarmann-Schulz, Achim Hoerauf, Andrew Majewski, John Horton, Sarah Sullivan, Eric A Ottesen, Thomas B Nutman
{"title":"在马里农村地区改善淋巴水肿的强化卫生护理中加入为期六周的强力霉素疗程的效果:为期24个月的双盲随机对照试验。","authors":"Yaya I Coulibaly, Abdoul F Diabate, Moussa Sangare, Sekou O Thera, Housseini Dolo, Salif S Doumbia, Siaka Y Coulibaly, Ayouba Diarra, Lamine Diarra, Diadje Tanapo, Michel E Coulibaly, Lamine Soumaoro, Abdallah A Diallo, Amatigue Zeguime, Yacouba Sanogo, Adama Berthe, Fatoumata Dite Nene Konipo, Charles Mackenzie, Mariana Stephens, Joseph P Shott, Jayla Norman, Ute Klarmann-Schulz, Achim Hoerauf, Andrew Majewski, John Horton, Sarah Sullivan, Eric A Ottesen, Thomas B Nutman","doi":"10.4269/ajtmh.23-0908","DOIUrl":null,"url":null,"abstract":"<p><p>Lymphedema (LE) is one the most disfiguring chronic manifestations of lymphatic filariasis. Its management relies primarily on limb hygiene and local care. A previous study in Ghana demonstrating a beneficial effect of doxycycline on LE led to the current multicenter trial on the efficacy of doxycycline in filarial LE. A randomized placebo-controlled trial was initiated in two rural health districts in Mali. Patients with LE stages 1-3 were randomized to receive either doxycycline (200 mg/day) or placebo over a 6-week monitored treatment period and were then followed every 6 months for 2 years. Both groups received materials for limb hygiene that was carried out daily for the entire 2-year study. The primary endpoint was lack of progression in LE stage at 24 months. One hundred patients were enrolled in each study arm. The baseline sociodemographic characteristics of each group were largely similar. There was no significant difference at month 24 after treatment initiation in the number of subjects showing progression in LE stage between the two treatment arms (P = 0.5921). Importantly, however, the number of attacks of acute adenolymphangitis (ADLA) was reduced in both arms, but there was no significant difference between the two groups at any follow-up time point (all P >0.23). Doxycycline was well tolerated in those receiving the drug. When added to daily self-administered limb hygiene, a 6-week course of doxycycline (200 mg) was not superior to placebo in increasing the improvement associated with hygiene alone in LE volume, stage, or frequency of ADLA attacks over a 24-month period.</p>","PeriodicalId":7752,"journal":{"name":"American Journal of Tropical Medicine and Hygiene","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11448486/pdf/","citationCount":"0","resultStr":"{\"title\":\"Effect of Adding a Six-Week Course of Doxycycline to Intensive Hygiene-Based Care for Improving Lymphedema in a Rural Setting of Mali: A Double-Blind, Randomized Controlled 24-Month Trial.\",\"authors\":\"Yaya I Coulibaly, Abdoul F Diabate, Moussa Sangare, Sekou O Thera, Housseini Dolo, Salif S Doumbia, Siaka Y Coulibaly, Ayouba Diarra, Lamine Diarra, Diadje Tanapo, Michel E Coulibaly, Lamine Soumaoro, Abdallah A Diallo, Amatigue Zeguime, Yacouba Sanogo, Adama Berthe, Fatoumata Dite Nene Konipo, Charles Mackenzie, Mariana Stephens, Joseph P Shott, Jayla Norman, Ute Klarmann-Schulz, Achim Hoerauf, Andrew Majewski, John Horton, Sarah Sullivan, Eric A Ottesen, Thomas B Nutman\",\"doi\":\"10.4269/ajtmh.23-0908\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Lymphedema (LE) is one the most disfiguring chronic manifestations of lymphatic filariasis. Its management relies primarily on limb hygiene and local care. A previous study in Ghana demonstrating a beneficial effect of doxycycline on LE led to the current multicenter trial on the efficacy of doxycycline in filarial LE. A randomized placebo-controlled trial was initiated in two rural health districts in Mali. Patients with LE stages 1-3 were randomized to receive either doxycycline (200 mg/day) or placebo over a 6-week monitored treatment period and were then followed every 6 months for 2 years. Both groups received materials for limb hygiene that was carried out daily for the entire 2-year study. The primary endpoint was lack of progression in LE stage at 24 months. One hundred patients were enrolled in each study arm. The baseline sociodemographic characteristics of each group were largely similar. There was no significant difference at month 24 after treatment initiation in the number of subjects showing progression in LE stage between the two treatment arms (P = 0.5921). Importantly, however, the number of attacks of acute adenolymphangitis (ADLA) was reduced in both arms, but there was no significant difference between the two groups at any follow-up time point (all P >0.23). Doxycycline was well tolerated in those receiving the drug. When added to daily self-administered limb hygiene, a 6-week course of doxycycline (200 mg) was not superior to placebo in increasing the improvement associated with hygiene alone in LE volume, stage, or frequency of ADLA attacks over a 24-month period.</p>\",\"PeriodicalId\":7752,\"journal\":{\"name\":\"American Journal of Tropical Medicine and Hygiene\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-07-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11448486/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American Journal of Tropical Medicine and Hygiene\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4269/ajtmh.23-0908\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/10/1 0:00:00\",\"PubModel\":\"Print\",\"JCR\":\"Q3\",\"JCRName\":\"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Tropical Medicine and Hygiene","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4269/ajtmh.23-0908","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"Print","JCR":"Q3","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0
摘要
淋巴水肿(LE)是淋巴丝虫病最难看的慢性表现之一。其治疗主要依靠肢体卫生和当地护理。此前在加纳进行的一项研究表明,多西环素对淋巴水肿有一定的疗效,因此目前正在进行一项多中心试验,研究多西环素对丝虫性淋巴水肿的疗效。马里的两个农村医疗区启动了一项随机安慰剂对照试验。1-3期丝虫病患者被随机分配接受强力霉素(200毫克/天)或安慰剂治疗,接受为期6周的监测治疗,然后每6个月随访一次,为期2年。两组患者都收到了肢体卫生材料,在整个两年的研究过程中,每天都要进行肢体卫生。主要终点是 24 个月时 LE 阶段没有进展。每个研究组均招募了 100 名患者。各组的基线社会人口学特征基本相似。在开始治疗后的第24个月,两个治疗组中出现LE阶段进展的受试者人数没有明显差异(P = 0.5921)。但重要的是,两组的急性腺淋巴管炎(ADLA)发作次数均有所减少,但在任何随访时间点,两组之间均无明显差异(P均大于0.23)。接受多西环素治疗的患者耐受性良好。在24个月的时间里,在每天自我管理肢体卫生的基础上加用强力霉素(200毫克)6周疗程,在改善LE体积、阶段或ADLA发作频率方面并不优于安慰剂。
Effect of Adding a Six-Week Course of Doxycycline to Intensive Hygiene-Based Care for Improving Lymphedema in a Rural Setting of Mali: A Double-Blind, Randomized Controlled 24-Month Trial.
Lymphedema (LE) is one the most disfiguring chronic manifestations of lymphatic filariasis. Its management relies primarily on limb hygiene and local care. A previous study in Ghana demonstrating a beneficial effect of doxycycline on LE led to the current multicenter trial on the efficacy of doxycycline in filarial LE. A randomized placebo-controlled trial was initiated in two rural health districts in Mali. Patients with LE stages 1-3 were randomized to receive either doxycycline (200 mg/day) or placebo over a 6-week monitored treatment period and were then followed every 6 months for 2 years. Both groups received materials for limb hygiene that was carried out daily for the entire 2-year study. The primary endpoint was lack of progression in LE stage at 24 months. One hundred patients were enrolled in each study arm. The baseline sociodemographic characteristics of each group were largely similar. There was no significant difference at month 24 after treatment initiation in the number of subjects showing progression in LE stage between the two treatment arms (P = 0.5921). Importantly, however, the number of attacks of acute adenolymphangitis (ADLA) was reduced in both arms, but there was no significant difference between the two groups at any follow-up time point (all P >0.23). Doxycycline was well tolerated in those receiving the drug. When added to daily self-administered limb hygiene, a 6-week course of doxycycline (200 mg) was not superior to placebo in increasing the improvement associated with hygiene alone in LE volume, stage, or frequency of ADLA attacks over a 24-month period.
期刊介绍:
The American Journal of Tropical Medicine and Hygiene, established in 1921, is published monthly by the American Society of Tropical Medicine and Hygiene. It is among the top-ranked tropical medicine journals in the world publishing original scientific articles and the latest science covering new research with an emphasis on population, clinical and laboratory science and the application of technology in the fields of tropical medicine, parasitology, immunology, infectious diseases, epidemiology, basic and molecular biology, virology and international medicine.
The Journal publishes unsolicited peer-reviewed manuscripts, review articles, short reports, images in Clinical Tropical Medicine, case studies, reports on the efficacy of new drugs and methods of treatment, prevention and control methodologies,new testing methods and equipment, book reports and Letters to the Editor. Topics range from applied epidemiology in such relevant areas as AIDS to the molecular biology of vaccine development.
The Journal is of interest to epidemiologists, parasitologists, virologists, clinicians, entomologists and public health officials who are concerned with health issues of the tropics, developing nations and emerging infectious diseases. Major granting institutions including philanthropic and governmental institutions active in the public health field, and medical and scientific libraries throughout the world purchase the Journal.
Two or more supplements to the Journal on topics of special interest are published annually. These supplements represent comprehensive and multidisciplinary discussions of issues of concern to tropical disease specialists and health issues of developing countries